Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

8.92
+4.2390.19%
Post-market: 8.960.0400+0.45%19:59 EDT
Volume:53.36M
Turnover:504.28M
Market Cap:621.26M
PE:-1.72
High:12.32
Open:4.80
Low:4.71
Close:4.69
Loading ...

Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity

TIPRANKS
·
Yesterday

Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna

TIPRANKS
·
Yesterday

Phathom Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Yesterday

Needham sees FDA’s positive CP ruling as best-case outcome for Phathom

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-WEC Energy, FuelCell Energy, Phathom Pharma

Reuters
·
Yesterday

Top Midday Gainers

MT Newswires Live
·
Yesterday

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

TIPRANKS
·
Yesterday

BUZZ-Phathom Pharma soars after FDA grants 10-year exclusivity shield for stomach drug

Reuters
·
Yesterday

Phathom says FDA to correct Orange Book for Voquenza exclusivity

TIPRANKS
·
Yesterday

Phathom Pharmaceuticals Secures FDA Approval for 10-Year Regulatory Exclusivity for VOQUEZNA® Tablets

Reuters
·
Yesterday

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for Voquezna® (Vonoprazan) Tablets Through May 3, 2032

THOMSON REUTERS
·
Yesterday

Director’s Bold Move: Phathom Pharmaceuticals Stock Purchase

TIPRANKS
·
24 May

Director James N. Topper Reports Acquisition of Common Shares in Phathom Pharmaceuticals Inc

Reuters
·
24 May

Phathom Pharmaceuticals Inc. Set to Participate in Goldman Sachs Annual Global Healthcare Conference 2025

Reuters
·
15 May

Director James N. Topper Reports Acquisition of Common Shares in Phathom Pharmaceuticals Inc

Reuters
·
14 May

Director Asit Parikh Reports Acquisition of Phathom Pharmaceuticals Common Shares

Reuters
·
09 May

Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
03 May

Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
02 May

Phathom Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $20 From $28

THOMSON REUTERS
·
02 May

Phathom Pharmaceuticals Reports Q1 2025 Financial Results

TIPRANKS
·
02 May